IN8bio, Inc. (6JH.MU)
| Previous close | 0.9550 |
| Open | 0.9550 |
| Bid | 0.8900 x N/A |
| Ask | 0.9850 x N/A |
| Day's range | 0.9550 - 0.9550 |
| 52-week range | 0.6400 - 2.9400 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 42.138M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress
NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, announced today a presentation at the European Hematology Association 2024 Congress, to be held June 13-16 in Madrid, Spain. “We’re excited to share the latest updated interim results from our Phase 1 trial evaluating our gamma-delta T cell therapy INB-100 after haploidentical stem cell transplantation for patients with leukemia at
- GlobeNewswire
IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024
NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company advancing innovative gamma-delta T cell therapies, presented in an oral session details about its robust and reproducible proprietary clinical-scale gamma-delta T cell manufacturing platform across different donor populations, at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting. In an oral presentation titled: “Healthy Donor vs. Patient Manufactured Autologous DeltE
- GlobeNewswire
IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
- Presented new preclinical data demonstrating proof-of-concept for non-signaling Chimeric Antigen Receptor (nsCAR) platform to effectively target cancer cells while preserving healthy tissue - Demonstrated potential of nsCAR platform to treat previously “undruggable” solid and liquid tumor targets - Announced peer-reviewed publication in ‘Frontiers in Immunology’ on IN8bio’s DeltEx Drug Resistant Immunotherapy (DRI) approach to newly diagnosed glioblastoma multiforme (GBM) - Dosed first patient
